Patients may also report any suspected adverse reactions associated with the use of health products to Health Canada by calling toll free at 1-86 or by visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax. Metformin is a first-line pharmacological treatment for patients with type 2 diabetes mellitus because of its favorable overall profile, including its glucose-lowering ability, weight-neutral effects, and low risk of hypoglycemia however, gastrointestinal (GI) intolerance may limit use in some patients. To report a suspected adverse reaction associated with the use of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) patients may contact Apotex by calling 1-80 (select prompt 2), by email at or by fax at 1-86 or 41.
Metformin can be of value in the treatment of obese diabetic patients. Clinical data demonstrates that administration of metformin hydrochloride in the fed state significantly increases the systemic delivery of metformin when compared to the fasted state.
Apo-Metformin ER is a once-daily formulation, which must be taken with food to ensure optimum delivery of metformin to the systemic circulation. Apo-Metformin ER may be used as monotherapy, or concomitantly with a sulfonylurea. Potentially impacted product and lot numbers for further information.ĪPO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets)ĪPO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) is indicated for the control of hyperglycemia in adult patients with type 2 (non-insulin-dependent, mature onset) diabetes, as an adjunct to dietary management, exercise, and weight reduction, or when insulin therapy is not appropriate.
0 kommentar(er)
